Amodiaquine-induced agranulocytosis: drug inhibition of myeloid colonies in the presence of patient's serum.
We report a patient who developed agranulocytosis following exposure to three drugs: amodiaquine, pyrimethamine and dipyrone. The combination of amodiaquine with the patient's serum, obtained during the agranulocytosis, inhibited in vitro granulocyte-monocyte colony-forming unit (CFU-GM) growth of autologous and allogeneic marrow. These results support the view that amodiaquine-induced agranulocytosis is immune in nature. This in vitro approach may be used to study the mechanism of drug-induced agranulocytosis, especially when patients are exposed to multiple drugs.
D000380:Agranulocytosis / Q000139:chemically induced*; D000655:Amodiaquine / Q000009:adverse effects*; D001854:Bone Marrow Cells; D003114:Colony-Forming Units Assay; D004177:Dipyrone / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008288:Malaria / Q000188:drug therapy; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D011739:Pyrimethamine / Q000627:therapeutic use; D013234:Stem Cells / Q000187:drug effects*
D000655:Amodiaquine; D004177:Dipyrone; D011739:Pyrimethamine